WealthPLAN Partners’s TherapeuticsMD TXMD Stock Holding History

WealthPLAN Partners’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-95	Closed	-$391	–	1100
2023 Q2	$391	Hold	95	–	–	﹤0.01%	1191
2023 Q1	$356	Buy	+95	New	+$456	﹤0.01%	1263

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WealthPLAN Partners's TXMD Position: Q3 2023 in Review

WealthPLAN Partners sold out of TherapeuticsMD (TXMD) in Q3 2023, closing a stake of 95 shares — an estimated $391 sold.

WealthPLAN Partners first reported a position in TXMD in Q1 2023 and held it in 2 quarters. The position peaked at $391 in Q2 2023. 36 funds tracked by Wall St. Rank hold TXMD as of Q3 2023.

WealthPLAN Partners reported no remaining TherapeuticsMD position as of Q3 2023 after selling out during the quarter.
WealthPLAN Partners sold 95 TherapeuticsMD shares in Q3 2023, an estimated $391.
WealthPLAN Partners first reported a position in TherapeuticsMD in Q1 2023 and held it in 2 quarters.
WealthPLAN Partners's TherapeuticsMD position peaked at $391 in Q2 2023.
36 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2023.

Based on WealthPLAN Partners's 13F filing for Q3 2023, filed 2 Nov 2023.